UA106591C2 - Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1 - Google Patents

Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1

Info

Publication number
UA106591C2
UA106591C2 UAA201102255A UAA201102255A UA106591C2 UA 106591 C2 UA106591 C2 UA 106591C2 UA A201102255 A UAA201102255 A UA A201102255A UA A201102255 A UAA201102255 A UA A201102255A UA 106591 C2 UA106591 C2 UA 106591C2
Authority
UA
Ukraine
Prior art keywords
interleukin
pharmaceutical formulation
insulin
interferon
hepatitis
Prior art date
Application number
UAA201102255A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Ігор Анатолієвіч Помиткін
Тамара Алєксандровна Віткалова
Original Assignee
Тамара Алєксандровна Віткалова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тамара Алєксандровна Віткалова filed Critical Тамара Алєксандровна Віткалова
Publication of UA106591C2 publication Critical patent/UA106591C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201102255A 2008-07-23 2008-07-23 Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1 UA106591C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/059643 WO2010009762A1 (fr) 2008-07-23 2008-07-23 Interféron et agent induisant l’inhibition de la protéine phosphatase 2a tel que l’interleukine 1 et éventuellement la ribavirine pour le traitement d’une infection à vhb ou vhc

Publications (1)

Publication Number Publication Date
UA106591C2 true UA106591C2 (uk) 2014-09-25

Family

ID=40996585

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201102255A UA106591C2 (uk) 2008-07-23 2008-07-23 Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1

Country Status (3)

Country Link
EA (1) EA022952B1 (fr)
UA (1) UA106591C2 (fr)
WO (1) WO2010009762A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2468815C1 (ru) * 2011-08-08 2012-12-10 Федеральное государственное бюджетное учреждение "Научный центр здоровья детей" Российской академии медицинских наук Способ повышения эффективности интерферонотерапии хронического гепатита с у детей
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
CN108366990B (zh) 2015-09-24 2021-09-03 加利福尼亚大学董事会 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
WO2022133494A1 (fr) * 2020-12-17 2022-06-23 The Regents Of The University Of California Composés antiviraux et leurs applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT858343E (pt) * 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO2003026686A1 (fr) * 2001-09-27 2003-04-03 Pomytkin Igor A Potentialisation des effets therapeutiques des interferons
WO2005071101A1 (fr) * 2004-01-23 2005-08-04 University Hospital Of Basel Traitement de hepatite c par augmentation de la methylation de stat1
WO2006032711A1 (fr) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Utilisation du facteur de croissance semblable a l'insuline de type i et de l'interferon alpha dans le traitement d'une maladie hepatique chronique, et kit et compositions contenant ledit facteur et ledit interferon
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.

Also Published As

Publication number Publication date
EA022952B1 (ru) 2016-03-31
EA201100322A8 (ru) 2013-06-28
EA201100322A1 (ru) 2011-10-31
WO2010009762A1 (fr) 2010-01-28

Similar Documents

Publication Publication Date Title
Girasole et al. Interleukin-11: a new cytokine critical for osteoclast development.
Patton et al. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells.
UA106591C2 (uk) Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1
JP2004525957A5 (fr)
Aman et al. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist
Zhang et al. Cytokines and pulmonary fibrosis
Jeong et al. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity
Fong et al. Tumor necrosis factor in the pathophysiology of infection and sepsis
McGee et al. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines
Gajewski et al. Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor.
Kimura et al. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6
Luo et al. Antiviral activity of type I and type III interferons against porcine reproductive and respiratory syndrome virus (PRRSV)
Rückerl et al. Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1
Ertenli et al. Pathologic thrombopoiesis of rheumatoid arthritis
Talmadge The pharmaceutics and delivery of therapeutic polypeptides and proteins
NO20065860L (no) Stabiliserte flytende interferonformuleringer
Pinkerton et al. Cultured human periodontal ligament cells constitutively express multiple osteotropic cytokines and growth factors, several of which are responsive to mechanical deformation
CA2522535A1 (fr) Composes heterocycliques se fixant aux recepteurs de chimiokine avec une efficacite accrue
Hamblin Lymphokines and interleukins
Gorny et al. IL-6, LIF, and TNF-α regulation of GM-CSF inhibition of osteoclastogenesis in vitro
EP1660682A4 (fr) Modulation antisens de l'expression de la kinase proteine activee par le mitogene p38
WO2006134195A8 (fr) Utilisation de la cytokine de la famille de l'interleukine-6 dans la preparation d'une composition pour une administration combinee avec un interferon-alpha
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
Kukita et al. Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells
WO2020231855A4 (fr) Nogapendékine alfa-inbakicept pour thérapies de stimulation immunitaire et traitement d'infections virales